Irbesso belongs to a group of medicines known as angiotensin-II receptor antagonists and prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower. Irbesso slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Irbesso is indicated for:
– treatment of essential hypertension;
– treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Subject to medical prescription.
Concentration and pharmaceutical form: 150 mg, 300 mg film-coated tablets